Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
45.13
+1.48 (3.39%)
Nov 17, 2025, 4:00 PM EST - Market closed
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.88M in the quarter ending September 30, 2025, with 43.69% growth. This brings the company's revenue in the last twelve months to $44.79M, up 36.26% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$44.79M
Revenue Growth
+36.26%
P/S Ratio
58.10
Revenue / Employee
$91,785
Employees
488
Market Cap
2.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AGIO News
- 14 days ago - Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
- 14 days ago - Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 18 days ago - Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Agios Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia - Business Wire
- 4 weeks ago - Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia - GlobeNewsWire
- 4 weeks ago - Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - GlobeNewsWire
- 2 months ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire